Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Leprosy Still Present in the US

By R&D Editors | November 10, 2008

Long believed to be a disease of biblical times, leprosy, also known as Hansen’s disease, continues to be seen in the United States. ‘Approximately 150 cases are diagnosed each year with 3,000 people in the U.S. currently being treated for leprosy,’ says James Krahenbuhl, Ph.D., director of the Health Resources Service Administration’s National Hansen’s Disease Program (NHDP) in Baton Rouge, LA. ‘We believe there are more cases of leprosy not identified due to the lack of awareness about the disease among physicians in the U.S., which is leading to misdiagnosis and wrong treatments for patients who are left to suffer with the debilitating damage caused by this disease.’

Although researchers do not clearly understand how leprosy is transmitted, they do know that it is a slow, chronic disease that attacks the peripheral nervous system and motor skills often leading to disability and disfigurement. According to the NHDP, the onset of infection and symptoms can take three to 10 years, making it difficult for researchers to find the origin of where or how people acquire the disease. As the disease progresses, patients lose their sense of touch in their fingers and toes leaving them open to repeated burns and cuts which then get infected. The effects of repeated damage will initiate bone absorption and motor nerve deterioration causing fingers to shorten and curve, resulting in a claw-like appearance. Although leprosy can be fully treated with medicine when diagnosed in early stages, once the disease has advanced nerve damage cannot be reversed.

Because many of the population in the U.S. affected by leprosy are immigrants in poor communities who primarily seek treatment in free clinics or emergency rooms, the NHDP says that many of those physicians are not familiar with the disease to make an accurate diagnosis. Therefore, many physicians mistake the skin lesions of leprosy for a fungus or ringworm and treat it with a topical cream. And, because leprosy is a slow-progressing disease, it can take months, if not longer, before the doctor or the patient realizes that the treatment isn’t working – giving the disease enough time to start destroying the nervous system.

Leprosy is most prevalent in the tropics and third world countries where there are poor living conditions and limited access to medical care. Due to changes in immigrant relocation, leprosy is now being diagnosed throughout the U.S. The NHDP sees approximately 30 cases each year among residents in southern Louisiana and the Gulf Coast of Texas who were born in the U.S. and who have never visited an endemic country. ‘As we see leprosy move toward internal regions of the States, it becomes more urgent to reach those physicians to let them know about the symptoms of this disease,’ explains Dr. Krahenbuhl.

Release Date: November 7, 2008
Source: American Society of Tropical Medicine and Hygiene

Related Articles Read More >

Parallel Bio’s embraces in-house drug development as FDA backs animal testing alternatives
R&D 100 Winner Spotlight: A closer look at Thermo Fisher Scientific’s trio of R&D 100 wins in 2025
Life sciences M&A hit $240B in 2025 as Big Pharma preps for patent cliffs
Hansoh Bio signs 32,000-sq.-ft. lab lease at Research Square in Rockville, MD
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2025 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE